2023 Virtual Series:
Psychiatry in the 21st Century: Where Might the Future Take Us?
Join us as we explore advances in modern psychiatric treatments straight from the experts. Expect to hear about a range of topics from interventional psychiatry updates and the new TAAR1 receptor to updates on the current state of cannabis and psychedelic research.
This is a 4-part series with sessions falling on the last Thursday of the month between January and April 2023. Sessions will run from 6:30-8 p.m.
Sessions:
Advances in Therapeutic Neuromodulation
January 26
Guest Speakers: Jeffrey I. Bennett, MD, LFAPA and Philip G. Janicak, MD
Dr. Jeffrey I. Bennett joined the faculty at Southern Illinois University School of Medicine in 2003 and is now Associate Professor of Psychiatry. Dr. Bennett received the Medical Innovators Award in 2013 for developmental of the TMS Clinic which he directs and in 2019 initiated the Intranasal Esketamine Clinic. He has held several posts (Residency Program Director; Director of the Division of Developmental Disabilities; and Psychiatry Clerkship Director). He received the APA Irma Bland Resident Teaching Award in 2009. In 2014, he became the Donnelly Family Endowed Professor in Developmental Disabilities and subsequently an SIU SOM Academy Scholar 2015. During his tenure at SIU, Dr. Bennett has participated in clinical trials research as the Principal Investigator for the REACH OUT, PRIDE, ATTAIN, FIRST, ORBIT, and ASPIRE studies. He is now a Principal Investigator for the RECOVER Study (LivaNova) investigating the efficacy and safety of Vagus Nerve Stimulation in Treatment Resistant Depression, and for several other studies including the Seelos Therapeutics SLS-002-201 study investigating safety and efficacy of intranasal racemic ketamine in adults with Major Depressive Disorder at imminent risk for suicide. He has served as a member of the local IRB and Grant Review Committee and currently chairs the Department of Psychiatry Industry Sponsored Research Studies Committee. Previously as an Instructor at the University of Chicago, he also served as a Neuropsychiatric Consultant for Tinley Park Mental Health Center and Midwest Neurological Rehabilitation Center in Waterford, Wisconsin (1992-93). He also consulted for W.A. Howe Development Center in Tinley Park, Illinois (1992-94). He served as Medical Director at Jacksonville Developmental Center (2011-2012). He is board certified in psychiatry. He currently serves as Secretary and as a past President for the Illinois Psychiatric Society. He is a member of the American Psychiatric Association Telepsychiatry and Membership Committees. He currently serves on the membership committee for the American Society of Clinical Psychopharmacology. He is a member of American Neuropsychiatric Association, American Medical Association, and the International College of Neuropsychopharmacology.
Dr. Philip Janicak is an Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association. He completed his medical training and psychiatric residency at Loyola University of Chicago in 1976. In 1978, he became a research psychiatrist at the Illinois State Psychiatric Institute. He was a Professor of Psychiatry and Pharmacology, the Medical Director of the Psychiatric Clinical Research Center, and the Associate Program Director for the NIH General Clinical Research Center at the University of Illinois Medical Center from 1994-2004. He then became a Professor of Psychiatry at Rush University and was the Director of the Rush Psychiatric Clinical Research and Transcranial Magnetic Stimulation Centers from 2004-2014. He developed and directed the TMS Center at Linden Oaks Medical Group from 2014-2017. Dr. Janicak’s primary research interests are in the assessment and treatment of mood and psychotic disorders. In this context, he has conducted over 60 clinical trials. He has been a NIH grant awardee as both a principal and co-investigator. He has authored, co-authored or edited over 500 publications in the psychiatric literature and is first author of the Principles and Practice of Psychopharmacotherapy. Dr. Janicak was the editor of the Psychopharm Review from 2004-2014 and presently serves on the Editorial Board of Current Psychiatry. He has also been a reviewer for several journals, including: The American Journal of Psychiatry, Biological Psychiatry, JAMA Psychiatry, Journal of the American Medical Association, Journal of ECT, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Psychiatric Annals, Psychiatry Research and Schizophrenia Research. Dr. Janicak was first listed in the Best Doctors of America since 1996 and Who’s Who in America in 2001. Dr. Janicak was named Psychiatrist of the Year by NAMI Illinois for 2003. In 2009, he received the John M. Davis Researcher of the Year Award from NAMI of Greater Chicago. In 2017, he was a recipient of the Who’s Who Albert Nelson Marquis Lifetime Achievement Award. In 2018, he was the recipient of the Illinois Psychiatric Society Educator of the Year Award. He has participated as a principal lecturer in over 500 courses, seminars, symposia and related professional presentations.
Back to the Future: Psychedelics in Psychiatry
February 23
Guest Speaker: Fernando Espi Forcen, MD, PhD
TAAR1: Science Behind a Potential New TAARget for Schizophrenia
March 30
Guest Speaker: LaGenia Bailey, PharmD
Current State of Cannabis in Psychiatry
April 27
Guest Speaker: TBD
Registration Coming Soon